PML and a tale of two drug companies.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D015766:Albendazole / Q000627:therapeutic use*; D001812:Blood-Brain Barrier; D002166:Camptothecin / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D004345:Drug Industry; D006801:Humans; D000077146:Irinotecan; D007577:JC Virus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D007968:Leukoencephalopathy, Progressive Multifocal / Q000150:complications / Q000188:drug therapy*; D016881:Microsporidiosis / Q000188:drug therapy*; D016133:Polymerase Chain Reaction; D019772:Topotecan
D000077146:Irinotecan; D019772:Topotecan; D015766:Albendazole; D002166:Camptothecin